Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group.
Stadtmauer EA, O'Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN, Brodsky I, Martino S, Lazarus HM, Erban JK, Sickles C, Glick JH. Stadtmauer EA, et al. Among authors: mangan kf. N Engl J Med. 2000 Apr 13;342(15):1069-76. doi: 10.1056/NEJM200004133421501. N Engl J Med. 2000. PMID: 10760307 Free article. Clinical Trial.
Economic analysis of conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer.
Schulman KA, Stadtmauer EA, Reed SD, Glick HA, Goldstein LJ, Pines JM, Jackman JA, Suzuki S, Styler MJ, Crilley PA, Klumpp TR, Mangan KF, Glick JH. Schulman KA, et al. Among authors: mangan kf. Bone Marrow Transplant. 2003 Feb;31(3):205-10. doi: 10.1038/sj.bmt.1703795. Bone Marrow Transplant. 2003. PMID: 12621482 Clinical Trial.
Phase II study of high-dose cyclophosphamide, etoposide, and carboplatin (CEC) followed by autologous hematopoietic stem cell rescue in women with metastatic or high-risk non-metastatic breast cancer: multivariate analysis of factors affecting survival and engraftment.
Klumpp TR, Goldberg SL, Magdalinski AJ, Mangan KF. Klumpp TR, et al. Among authors: mangan kf. Bone Marrow Transplant. 1997 Aug;20(4):273-81. doi: 10.1038/sj.bmt.1700882. Bone Marrow Transplant. 1997. PMID: 9285541 Clinical Trial.
Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
Klumpp TR, Mangan KF, Glenn LD, Malaspina DR, Cropper T, Mullaney M, Macdonald JS. Klumpp TR, et al. Among authors: mangan kf. Bone Marrow Transplant. 1993 Oct;12(4):337-45. Bone Marrow Transplant. 1993. PMID: 7506091 Clinical Trial.
A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients.
Shpall EJ, Wheeler CA, Turner SA, Yanovich S, Brown RA, Pecora AL, Shea TC, Mangan KF, Williams SF, LeMaistre CF, Long GD, Jones R, Davis MW, Murphy-Filkins R, Parker WR, Glaspy JA. Shpall EJ, et al. Among authors: mangan kf. Blood. 1999 Apr 15;93(8):2491-501. Blood. 1999. PMID: 10194427 Free article. Clinical Trial.
75 results